We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
P8‐104: The clinical outcomes of nivolumab plus ipilimumab combined with platinum‐based chemotherapy, single‐center, retrospective analysis.
- Abstract
B Methods b : We retrospectively examined overall response rate (ORR), AEs as well as PD-L1 status on chemotherapy naïve advanced NSCLC patients treated with chemotherapy combined with nivolumab and ipilimumab (NIP group) or PD-1/PD-L1 inhibitors (PP group) from April 2020 to May 2021. B Conclusions b : Nivolumab, ipilimumab, and platinum-based chemotherapy may be the preferred treatment options for patients with NSCLC with low PD-L1 expression. The purpose of this study is to examine the anti-tumor effects and adverse events (AEs) of NSCLC patients treated with chemotherapy combined with nivolumab plus ipilimumab compared to that with PD-1/PD-L1 inhibitors.
- Subjects
TREATMENT effectiveness; NIVOLUMAB; IPILIMUMAB; CANCER chemotherapy
- Publication
Respirology, 2021, Vol 26, p329
- ISSN
1323-7799
- Publication type
Article
- DOI
10.1111/resp.14150_616